Novartis options osteoporosis drug

Novartis inked a deal to option a Phase II drug for osteoporosis from Radius Health. The deal is worth more than $500 million in potential milestone payments and Novartis' venture arm is making a $10 million investment in the Cambridge, MA-based biotech. Ipsen, which licensed the drug to Radius in 2005, is positioned to earn up to $125 million of that licensing money. The therapy, BA058, is a parathyroid hormone-related protein.

"This major commitment by the MPM Bio IV NVS Strategic Fund reflects our belief in the potential of BA058 to address important unmet needs for osteoporosis patients in the near future, and in the attractive commercial potential of Radius," said Ansbert Gadicke, MD, General Partner of MPM Capital and General Partner of the MPM Bio IV NVS Strategic Fund/

- read the release for more information

ALSO: Novartis says it's not interested in merging with another Big Pharma player--but CEO Daniel Vasella (photo) still won't comment on a rumored takeover of German rival Bayer. Report

Related Articles:
Novartis pays big for roster of new vaccines. Report
Cash-rich Novartis CEO mulls biotech buyouts. Report
Novartis touts pipeline. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.